TY - JOUR
T1 - Gender differences in early systemic sclerosis patients: A report from the EULAR scleroderma trials and research group (EUSTAR) database
AU - Carreira, P. E.
AU - Carmona, L.
AU - Joven, B. E.
AU - Loza, E.
AU - Andreu, J. L.
AU - Riemekasten, G.
AU - Vettori, S.
AU - Balbir-Gurman, A.
AU - Airò, P.
AU - Walker, U. A.
AU - Damjanov, N.
AU - Matucci-Cerinic, M.
AU - Ananieva, L. P.
AU - Rednic, S.
AU - Czirják, L.
AU - Distler, O.
AU - Farge, D.
AU - Hesselstrand, R.
AU - Corrado, A.
AU - Caramaschi, P.
AU - Tikly, M.
AU - Allanore, Y.
N1 - Funding Information:
The authors and all EUSTAR centres are grateful for the support of the European League Against Rheumatism until 2013. We also would like to thank all EUSTAR collaborators who are listed in the online additional file 1, the patients who gave their consent to participate in EUSTAR, and the support from the Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness) and Merck Sharp and Dome.
Funding Information:
EUSTAR was supported by the Eu ropean League Against Rheumatism until 2013.This work was partially supported by FIS grant 11/01506 from the Instituto de Salud Carlos III, Spain (Spanish Ministry of Economy and Competitiveness), and from an unrestricted grant from Merck Sharp and Dome to the Instituto de Investigación del Hospital 12 de Octubre, Madrid (2014 0062).
Funding Information:
O. Distler had consultancy relation ship and/or has received research fund ing from Actelion, AnaMar, Bayer, Boehringer Ingelheim, Catenion, CSL Behring, ChemomAb, Roche, GSK, Inventiva, Italfarmaco, Lilly, Medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Sanofi and UCB in the area of potential treatments of scleroderma and its complications. In addition, Prof. Distler has a patent mir-29 for the treatment of systemic sclerosis licensed. S. Vettori has received speaking fees from Pfizer, Ab-bvie, Bristol-Myers Squibb, consultant fee from Thermofischer and Educational support from Pfizer, Roche; E. Loza and L. Carmona have received research funding from Abbvie, MSD, Pfizer, Roche, Novartis, BMS, UCB. J.L. Andreu has received funding to attend courses and congresses from Pfizer, Abbvie, Gebro, Menarini, speaking fee from Abbvie, GSK, Roche, UCB, and consultant fee from UCB and GSK. M. Matucci-Cerinic has received speaker bureau and research grants from BMS and Pfizer, and consultancy and research grant from Eli Lilly. All the other authors have declared no competing interests.
Publisher Copyright:
© COPYRIGHT CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2018.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/9/29
Y1 - 2018/9/29
N2 - Objective: To describe differences in clinical presentation between men and women in a large group of patients with early (<3 years' duration) systemic sclerosis (SSc) according to disease subsets. Methods: A cross-sectional analysis of the prospective EULAR Scleroderma Trial and Research database (EUS-TAR) was performed. Patients fulfilling preliminary ACR 1980 classification criteria for SSc, with less than 3 years from the first non-Raynaud's symptom at first entry, were selected. A group of patients with less than 3 years from the first SSc symptom, including Raynaud's phenomenon, was also analysed. SSc related variables, including antibodies, SSc subsets, disease activity and organ involvement were included. Descriptive and bivariate analyses were performed. Results: A total of 1,027 patients were included, 90% Caucasian, 80% women, and 40% with diffuse cutaneous disease. In early stages of SSc, men showed more frequently than women active disease, diffuse cutaneous subset, anti-Scl-70 antibodies, elevated acute phase reactants, muscular and pulmonary involvement. Differences between men and women were confirmed in the limited, but not in the diffuse SSc subset. The results were similar when 650 patients with less than three years from the first SSc symptom, including Raynaud's phenomenon, were analysed. Conclusion: In early stages of SSc, men present signs and symptoms of more severe disease. In the limited disease subset, men might appear with clinical features and organ involvement similar to those of the diffuse subgroup. In clinical practice, the identification of such differences might help to select the appropriate management for each particular patient.
AB - Objective: To describe differences in clinical presentation between men and women in a large group of patients with early (<3 years' duration) systemic sclerosis (SSc) according to disease subsets. Methods: A cross-sectional analysis of the prospective EULAR Scleroderma Trial and Research database (EUS-TAR) was performed. Patients fulfilling preliminary ACR 1980 classification criteria for SSc, with less than 3 years from the first non-Raynaud's symptom at first entry, were selected. A group of patients with less than 3 years from the first SSc symptom, including Raynaud's phenomenon, was also analysed. SSc related variables, including antibodies, SSc subsets, disease activity and organ involvement were included. Descriptive and bivariate analyses were performed. Results: A total of 1,027 patients were included, 90% Caucasian, 80% women, and 40% with diffuse cutaneous disease. In early stages of SSc, men showed more frequently than women active disease, diffuse cutaneous subset, anti-Scl-70 antibodies, elevated acute phase reactants, muscular and pulmonary involvement. Differences between men and women were confirmed in the limited, but not in the diffuse SSc subset. The results were similar when 650 patients with less than three years from the first SSc symptom, including Raynaud's phenomenon, were analysed. Conclusion: In early stages of SSc, men present signs and symptoms of more severe disease. In the limited disease subset, men might appear with clinical features and organ involvement similar to those of the diffuse subgroup. In clinical practice, the identification of such differences might help to select the appropriate management for each particular patient.
UR - http://www.scopus.com/inward/record.url?scp=85054385631&partnerID=8YFLogxK
M3 - Journal articles
C2 - 30277860
AN - SCOPUS:85054385631
SN - 0392-856X
VL - 36
SP - S68-S75
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
ER -